Notice Number: NOT-HL-15-286
Key Dates
Release Date: November 25, 2015
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
On November 17, 2015, the NHLBI issued Funding Opportunity Announcement (FOA) RFA-HL-17-008 "Pulmonary and Cardiovascular Consequences of Inhaled Nicotine (R01)". This Notice provides specific submission information to applicants regarding the Senior/Key Person Profile and the Review Criteria.
The following section of the FOA are revised accordingly:
Currently Reads
Section IV. Application and Submission Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Modified to Read
Section IV. Application and Submission Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Where applicable to the proposed specific research aims, describe relevant expertise and experience in such areas as aerosol sciences, inhalation dosimetry, pharmacology, immunology, molecular biology, developmental biology, cardiology, and pulmonology. Describe how proposed personnel will collaborate to provide relevant expertise.
All other aspects of the FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Lisa Postow, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: [email protected]